Standard requirement of a microbiological quality control program for the manufacture of human mesenchymal stem cells for clinical use by Gálvez Martín, Patricia et al.
1 
 
Full title 
Standard requirement of a microbiological quality control program for the manufacture 
of human mesenchymal stem cells for clinical use  
 
Running title 
Quality control program for the manufacture of mesenchymal stem cells 
 
Authors 
PATRICIA GALVEZ1, BEATRIZ CLARES2, MARIA BERMEJO1, ABDELKRIM 
HMADCHA1, 3, * and BERNAT SORIA1, 3, * 
Affiliations 
 
1 Department of Stem Cells, Andalusian Center for Molecular Biology and Regenerative 
Medicine (CABIMER), Cartuja-93 Scientific and Technological Park, Americo 
Vespucio Ave s/n. 41092, Seville, Spain.  
 
2 Department of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, 
Campus of Cartuja, 18071, University of Granada, Spain.  
 
3 Centre for Network Biomedical Research on Diabetes and Associated Metabolic 
Diseases (CIBERDEM), Bosanova Street 69, 6th floor, 08017 Barcelona, Spain 
 
*These authors share the senior authorship  
 
Correspondence: Patricia Gálvez Martín, Abdelkrim Hmadcha and Bernat Soria,  
Centro Andaluz de Biología Molecular y Medicina Regenerativa (CABIMER) 
Avenida Américo Vespucio s/n 
41092, Sevilla, Spain 
Tel.: +34 954 468004 
Fax: +34 954 461664 
E-mails:  
patricia.galvez@cabimer.es; karim.hmadcha@cabimer.es and bernat.soria@cabimer.es   
 
 
 
 
 
2 
 
Abstract 
Background: The manufacturing of human mesenchymal stem cells (hMSCs) as cell-
based products for clinical use should be performed with appropriate controls that 
ensure its safety and quality. The use of hMSCs in cell therapy has increased 
considerably in the past few years. In line with this, the assessment and management of 
contamination risks by microbial agents that could affect the quality of cells and the 
safety of patients have to be considered. It is necessary to implant a quality control 
program (QCP) covering the entire procedure of the ex vivo expansion, from the source 
of cells, starting materials and reagents, such as intermediate products to the final 
cellular medicine.  
Methods: We defined a QCP to detect microbiological contamination during 
manufacturing of autologous hMSCs for clinical application. The methods used include, 
sterility test, Gram stain, detection of mycoplasma, endotoxin assay and microbiological 
monitoring in process according to the European Pharmacopoeia (Ph. Eur.) and each 
analytical technique was validated in accordance with three different cell cultures.  
Results:  Results showed no microbiological contamination in any phases of the 
cultures, meeting all the acceptance criteria for sterility test, detection of mycoplasma 
and endotoxin, environmental and staff monitoring. Each analytical technique was 
validated demonstrating the sensitivity, limit of detection and robustness of the method.   
Discussion: The quality and safety of MSCs must be controlled to ensure their final use 
in patients. The evaluation of the proposed QCP revealed satisfactory results in order to 
standardize this procedure for clinical use of cells. 
Key Words: cell therapy, endotoxin, mesenchymal stem cell, mycoplasma, quality 
control, sterility, validation 
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Abbreviations 
 
BET       Bacterial Endotoxin Test  
CTMP    Cell-based Therapy Medical Product  
CFU       Colony Forming Unit  
DMEM   Dulbecco´s Modified Eagle´s Medium  
EL         Endotoxin Limit 
EU         Endotoxin Unit  
EDQM  European Directorate for the Quality of Medicines 
Ph. Eur.           European Pharmacopoeia  
FBS        Fetal Bovine Serum  
GMP       Good Manufacturing Practice  
HIV         Human Immunodeficiency Virus 
hMSCs    Human Mesenchymal Stem Cells   
IgM        Immunoglobulin  
ICH          International Conference on Harmonization  
λ            Labelled Lysate Sensitivity 
LOD       Limit of Detection  
LAL         Limulus Amebocyte Lysate  
MCB       Master Cell Bank     
MVD     Maximum Valid Dilution  
NAT        Nucleic Acid Amplification Technique  
PBS        Phosphate Buffered Saline 
PCR       Polymerase Chain Reaction  
QCP       Quality Control Program  
SDC      Sabouraud Dextrosa Cloramfenicol 
TPB       Thioglycollate Penase Broth 
TSA      Trypcase Soja Agar   
TSPB     Tryptic Soy Penase Broth  
WCB      Working Cell Bank 
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Introduction 
Cell-based therapy has led to the development of new biological medicines to repair, 
replace or recover the biological function of damaged tissues and organs (1). Among 
cell types used for this propose, hMSC are considered as Cell-based Therapy Medical 
Product (CTMP) and should be handled with appropriate controls to ensure their safety, 
quality and efficacy as a final medicine (8). (9).  
The manufacture of hMSCs involves an ex vivo expansion for a relatively long period of 
time, which leads to a risk of contamination by microbiological agents that could affect 
the quality and safety of the cells (10). Contamination of a CTMP can cause adverse 
reactions in patients (e.g. fever, chills, infections, irreversible septic shock) and even 
death (10, 11). Therefore it will be necessary to standardize and validate all procedures 
and analytical techniques involved in the manufacture of CTMP (12), posing a Quality 
Control Program (QCP). 
A QCP should ensure that cells have been manufactured in aseptic conditions, under 
GMP conditions to minimize the contamination risk of the cell medicine and thus, to 
ensure the safety of patients and the quality of the medicine. This program will 
comprise the whole process of ex vivo expansion, starting from type of cells, source of 
materials, reagents and intermediate products, to CTMP, the final cellular medicine (13-
14). Chiefly, because the cells must be viable for their administration and sould not be 
sterilized by physico-chemical methods, in this in this scenario a risk analysis must be 
performed to determine the posibilities of microbiological contamination before 
designing a QCP. For a QCP apllied to a CTMP, each analytical technique should be 
justified, and the amount and type of evidence required for microbiological quality 
control defined according to the different pharmacopoeias, as well as, the guidelines 
issued by regulatory agencies and International Conference on Harmonisation (ICH) in 
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particular Quality guidelines (15, 16). Validation studies must be performed for each 
analytical technique to demonstrate and verify that the procedure adopted at each site 
laboratory does not alter the method and consequently the result (17).  
The aim of this study was to develop a microbial QCP of a CTMP (Figure 1), for the 
long-term expansion of human adipose derived MSCs. In particular, the manufactured 
medicine was an injectable cell suspension, elaborated by suspending the active 
principle (hMSCs) and other additives (culture medium or packing medium), packaged 
in a suitable container to be administered parenterally (intramuscular, intravenous, intra-
arterial). Contamination by bacteria, fungi, mycoplasma and bacterial endotoxin 
concentration were analyzed in line with QCP proposed in different phases such as 
Master Cell Bank (MCB), Working Cell Bank (WCB) and in the final cellular medicine. 
Each analytical technique was validated by three different cell cultures process. 
 
Materials and Methods 
This study was performed in the quality control unit of the CABIMER’s GMP facility 
authorized by the Spanish Agency of Medicines and Medical Devices and regularly 
inspected by the Spanish competent authorities. 
 
1. Isolation and culture of hMSCs 
Autologous hMSCs were isolated from abdobiminal adipose tissue biopsies of patients 
enrolled in a Phase I/II clinical trial. All donors provided informed consent that was 
formerly approved by local and regional medical research ethics committees. Each 
patient was appropriately screened and tested for human pathogens. In particular, the 
presence of Human Immunodeficiency Virus (HIV), hepatitis B and hepatitis C virus 
were analyzed. On the other hand, all starting materials and reagents required for the 
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expansion were analyzed to certify that they were sterile and endotoxin-free. 
Cells were isolated from human adipose tissue by enzymatic digestion with collagenase 
(2 mg collagenase/1 g adipose tissue) (Roche Farma, Reinach, BL, Switzerland), 
centrifuged at 400 g for 10 min, filtered and washed with Phosphate Buffered Saline 
(PBS) (Sigma-Aldrich, St. Louis, MO, USA) to obtain the stromal cells. These cells 
were suspended and plated at medium density of 12-20 x 104 cells/cm2 in culture flasks 
(Nunc, Roskilde, Roskilde-DK4 000, Denmark) with expansion medium composed by 
Dulbecco´s Modified Eagle´s Medium (DMEM), supplemented with 10% Fetal Bovine 
Serum (FBS), 1% of 10,000 IU/mL Penicillin, 10 mg/mL Streptomycin, 2% of 200 mM 
L-alanine solution and 1% of 200 mM L-glutamina, (all Sigma-Aldrich, St. Louis, MO, 
USA). After 24 hours, non-adherent cells were removed by replacing the expansion 
medium. The medium was replaced every 2 or 3 days a week. Cells were harvested 
upon reaching 80% confluence, and subcultured using 0.25% trypsin (Gibco, 
Invitrogen, Grand Island, NY, USA) in expansion medium, and plated at medium 
density, 3500−5500 cells/cm2. Cells were cultured under 95% relative humidity, at 37 
°C and 5% CO2.  Three different processes of ex vivo expansion hMSCs were carried 
out (named: 1, 2 and 3) from passages 3-4 to analyze their microbiological quality. For 
the final product, cells were packed at concentration of 1 × 106 cells/mL with 1 mL of 
packaging medium composed by 50% of Glucose 5%, 45% of Lactated Ringer’s 
solution and 55% of Albumin 20% (Grifols, Barcelona, Spain). hMSCs were packed in 
10mL Luer-lock syringes (Becton Dickinson and Company, Franklin Lakes, NJ, USA). 
 
2. Sterility test and Gram stain 
The test was carried out in different phases (MCB, WCB and final cellular medicine), 
by direct inoculation of 1 mL of intermediate product (supernatant) or final suspension 
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in the microbiology medium, so that volume of the product is not more than 10 per cent 
of the volume of the medium but not less than 1 ml (18). Two media were used: 
Thioglycollate Penase Broth 125 mL (TPB) (BDH Prolabo, Mexico D.F., Mexico), to 
detect anaerobic and aerobic bacteria, and Tryptic Soy Penase Broth 125 mL (TSPB) 
(BDH Prolabo, Mexico D.F., Mexico), which is a soybean casein digest medium to 
detect fungi and aerobic bacteria.  For each media (TPB and TSPB), both sterility test 
and growth promotion test of aerobes, anaerobes and fungi were verified before testing, 
the strains used in the growth promotion test are indicated in the Table I. A negative 
control was included inoculating 1 mL of 0.9% sterile NaCl (bioMérieux, Marcy 
l'Etoile, France) for each medium. The inoculated media were incubated for 14 days at 
35 ºC and 22 ºC for TPB and TSPB, respectively. If microbial growth appears after 14 
days, the medium will show turbidity. 
Sterility test was performed as soon as possible after sample collection, which was 
stored at 5 ± 3 ºC for up to 24 hours (19) to avoid phagocytosis of microorganisms by 
cells present in the sample. This assay was performed in aseptic conditions with an 
isolator HPI-4PI-S (Esco Technologies, Inc., Hatboro, PA, USA). 
Additionally, in each final cellular medicine for the three cultures, the presence/absence 
of colony forming unit (cfu) was examined by standard procedure of Gram staining 
(20). Spanish Agency of Medicines and Medical Devices recommends that Gram 
staining should be performed before releasing the medicine to verify that there is no 
contamination.  If the Gram stain is positive, the cells will not be administered. 
Picture of Gram stains were taken using bright field microscope (Zeiss Axioskop 40, 
Carl Zeiss Mediatec AG, Jena, Germany). The stains were photographed by a 
microscope Zeiss Axioskop 40 (Carl Zeiss Mediatec AG, Jena, Germany), data not 
shown. 
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3. Detection of mycoplasma  
The test was carried out in different phases (MCB, WCB and final cellular medicine), 
cells are centrifuged and resuspended in  ¿….. µL/mL? the expansion medium and the 
detection of mycoplasma in the final cellular medicine was as previously described (21). 
In order to perform this assay, 5 × 105 cells in 500 µL of supernatant were used. Briefly, 
the sample was introduced in the dry block thermostat (TDB-120, Biosan Ltd., Riga, 
Latvia) to inactivate DNAses at 95 ºC for 10 min to avoid mycoplasma DNA 
degradation. Then, genomic DNA extraction was performed by the method of MB DNA 
(Minerva Biolabs, Berlin, Germany), which is sensitive for mycoplasma genomes.  
DNA was amplified by the Nucleic Acid Amplification Technique (NAT) with a PCR 
Mycoplasma detection kit (VenorGeM, Minerva Biolabs, Berlin, Germany). The DNA 
polymerase used for the amplification was MB Taq DNA polymerase (Minerva Biolabs, 
Berlin, Germany). The PCR device utilized was a Life Express thermal cycler (Bioer 
Technology Co., Hangzhou, P. R. China). The amplification products were analyzed by 
gel electrophoresis in the FlashGel® DNA System containing ethidium bromide (Lonza, 
Walkersville, MD, USA). The bands of any PCR amplicons were visualized by UV 
translumination. They were identified by comparing them with the bands visible in the 
positive control and the negative control reaction. The presence of mycoplasma was 
indicated by an amplification product at approximately 267 bp. A 191 bp band in every 
lane was indicated a successfully performed PCR without polymerase inhibition. The 
samples were analyzed before to 24 h after their collection, which after inactivation 
were stored for 6 days from 2 ºC to 8 ºC (22). 
 
4. Endotoxin assay 
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The bacterial endotoxin test method (BET) was used to detect the endotoxin unit (EU) 
by the Gel-Clot technique Limulus Amebocyte Lysate (LAL) (Pyrogent Ultra Lonza, 
Walkersville, MD, USA) (23, 24) from the sample in different phases (MCB, WCB and 
final cellular medicine). For the endotoxin assay in the final cellular medicine, cells are 
centrifuged and the resulting pellet is resuspended in ¿….. µL/mL? the expansion 
medium. 1/10 dilution of sample was necessary (100 µL of sample in 900 µL of water 
for BET), this dilution did not exceed the Maximum Valid Dilution (MVD). Then, 100 
µL of LAL and 100 µL of the diluted sample were mixed in a pyrogen-free tube (Lonza, 
Walkersville, MD, USA). Each sample also included a negative control (100 µL of LAL 
and 100 µL water for BET), and two different positive controls (100 µL of LAL and 
100 µL of 2λ/diluted test solution or 2λ/ water for BET). Each dilution was assayed in 
duplicate. All tubes were incubated at 37 ºC for 1 h in a water bath (Grant Instruments 
Ltd., Cambridge, UK). Each tube was examined to observe the presence/absence of 
gelation. The storage conditions of the samples in this assay are not defined, so each 
laboratory should define and validate those conditions. 
 
4.1. Storage stability testing 
To determine sample storage conditions, a study was performed using a purified 
standard control of endotoxin from Escherichia coli (ATCC 12014) 10 ng/vial with a 
potency of 4 EU/ng (Lonza, Walkersville, MD, USA). The samples were prepared 
adding 200 µL of standard control and 1800 µL of sample obtaining a solution of 0.8 
EU/mL. 2 mL solution was stored at 4 °C and −20 °C for 6 months in duplicate, and 
analyzed at different times (24 h, 48 h, 7 days, 14 days, 28 days, 2 months, 3 months, 4 
months, 5 months and 6 months). For each assay the storage sample was vigorously 
vortexed for 15 min. Then 100 µL of stored sample were mixed with 900 µL of water 
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for BET obtaining a dilution 1:10.  Equally, a negative control was evaluated in each 
assay. 
 
5. Microbiological monitoring in process 
An environmental microbiological monitoring plan was carried out to control the air, 
surfaces and staff in accordance with the European Union standards: EudraLex - 
Volume 4 GMP guidelines. The environmental and staff monitoring were conducted 
during the manufacturing process and the sterility assay in work areas (laminar flow 
cabin and isolator, respectively) with settle plates. Two media were used, Trypcase Soja 
Agar (TSA) (bioMérieux, Marcy l'Etoile, France) for detection of bacteria and 
Sabouraud Dextrose Chloramphenicol (SDC) (bioMérieux, Marcy l'Etoile, France) for 
fungi. The plates were incubated for 2 days at 35 ºC for TSA and 5 days at 22 ºC for 
SDC (25). 
For environmental monitoring, two settle plates (TSA and SDC) were exposed during 
each handling near the activity for a maximum of 4 h. For staff monitoring, when work 
shift finished, the operator gloves print (5 fingers) were monitored in each media (TSA 
and SDC).  
 
6. Analytical method validation  
Analytical methods of sterility, mycoplasma and endotoxin are “limit tests” analytical 
procedures, for this, an investigation of specificity; limit of detection (LOD) should be 
conducted during their validation according to ICH Q2 (26). In the development phase 
of an analytical procedure, robustness should also be considered GMP (27).  
The validation of sterility test was carried out in the intermediate product (cells with 
expansion medium) and in the final cellular medicine (cells and packaging medium), 
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each in triplicate. (Aquí defines los productos “intermediate and final” sin embargo no 
lo especificas en los apartados anteriores). 
Validation detection of mycoplasma and endotoxin assay was carried out with three 
samples of intermediate product (phase of MCB) of each culture (1, 2 and 3). 
 
6.1. Validation of sterility test. 
Validation was carried out to verify if the antimicrobial activity of the intermediate 
product and final cellular medicine had been satisfactorily eliminated under the 
conditions of the test (18, 19). Specificity for sterility test was analyzed by absence of 
false positive results (28), to determine LOD, a visual evaluation of turbidy was 
performed (18) and the robustness of these methods was studied by the reproducibility 
of the procedures. 
The test was validated with respect to LOD accepted by Pharmacopoeia, with an 
inoculum not more than 100 cfu (BioBall SingleShot - bioMérieux, France).  BioBall is 
an accredited reference material which contains a precise number of between 28 and 30 
cfu with a standard deviation of 3 cfu (18).  The validation was based on the 
inoculation, in a laminar flow cabinet BIOII-A (Telstar S.A., Madrid, Spain), of six 
different viable microorganisms, in each medium (TSB and TSPB) with 1 mL of 
supernatant and of final suspension. The microorganisms used for the validation are 
indicated in Table I.  
 
All media were incubated for 3 days for bacteria (Clostridium sporogenes, 
Pseudomonas aeruginosa, Staphylococcus aureus and Bacillus subtilis) and 5 days for 
fungi (Aspegillus niger and Candida albicans) at 35 ºC and 22 ºC for TPB and TSPB, 
respectively. For each microorganism a Gram stain was performed at the end of 
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incubation to confirm microorganism identity as well as a growth promotion test as a 
positive control. 
 
6.2. Validation of mycoplasma detection test 
Demonstration of specificity requires the use of a suitable range of bacterial species 
other than mycoplasmas. Bacterial genera with close phylogenetic relation to 
mycoplasmas are most appropriate for this validation, e.g. Lactobacillus (21). To 
determine the LOD for mycoplasma assay, the performance and reproducibility of the 
analytical procedure with a reference strain known as Mycoplasma orale (NCTC 10112) 
(29) was demonstrated. The LOD studied was 10 cfu/mL of M. orale (21).  
Each sample (5 × 105 cells by 500 µL of supernatant) was inoculated by M. orale with a 
final concentration of 10 cfu/mL. M. orale reference strain was obtained from European 
Directorate for the Quality of Medicines (EDQM). Briefly, in the inoculated samples, 
the mycoplasma assay was carried out 8 times for each sample in the same PCR assay. 
This procedure was repeated three times on different days to analyze the variability and 
robustness (30). 
 
6.3. Validation of endotoxin assay 
To validate the analytical procedure used for endotoxin assay, two studies were 
conducted: confirmation of the labelled lysate sensitivity and test for interfering factors.  
Specificity was demonstrated by the absence of interfering factors, for determining of 
LOD, a visual evaluation of the gelation was performed with a lysate sensitivity of 0.03 
EU/mL and the robustness was studied by the reproducibility (23).  
 
6.3.1. Confirmation of the labelled lysate sensitivity 
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This study was performed in three different batches of LAL to confirm the labelled 
lysate sensitivity (λ), which must be 0.03 EU/mL (23). λ was the antilog10 of this mean 
log endpoint (the last positive result in the series of endotoxin decreasing 
concentration). 
 For each batch, 4 endotoxin standard dilutions were used (2 λ, 1 λ, 0.5 λ and 0.25 λ). In 
a pyrogen-free tube with 100 µL of LAL, 100 µL of each standard dilution were added. 
Each dilution was assayed in quadruplicate. All tubes were incubated at 37 ºC for 1 h in 
water bath. Then, the presence/absence of gelation in each tube was observed, and the 
endpoints were determined. Each endpoint was converted to log10 and the mean and the 
antilog10 were calculated.  
 
6.3.2. Test for interfering factors 
This study was performed in three samples of intermediate product (phase of MCB) to 
check the presence of interfering factors. Test solution was used at a dilution 1:10 (less 
than the MVD). Four solutions were necessary named A, B, C and D. Solution A (4 
replicates of test solution) was the diluted sample in water for BET (1:10). Solution B 
(B consisted of 4 replicates of each concentrations equivalent to 2λ, λ, 0.5λ and 0.25λ 
by diluting the standard endotoxin with test solution) was prepared concentrations of 2 
λ, 1 λ, 0.5 λ and 0.25 λ. 2 λ was elaborated with 100 µL standard solution of 20 λ and 
900 µL of diluted sample. 1 λ was manufactured with 100 µL solution of 2 λ and 100 
µL of diluted sample. 0.5 λ was made up with 100 µL solution of λ and 100 µL of 
diluted sample. 0.25 λ was produced with 100 µL solution of 0.5 λ and 100 µL of 
diluted sample. Solution C (2 replicates of each concentrations equivalent to 2λ, λ, 0.5λ 
and 0.25λ by diluting the standard endotoxin with water for BET) was standard 
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concentrations of 2 λ, 1 λ, 0.5 λ and 0.25 λ. Solution D (2 replicates of water for BET) 
was the water for BET. 
In a pyrogen-free tube 100 µL of each solution (A, B, C, D) was added with 100 µL of 
LAL. All tubes were incubated at 37 ºC for 1 h in water bath. Solution A and B were 
assayed in quadruplicate and solution C and D in duplicate.  Then the presence/absence 
of gelation was observed.  
 
Results 
 
1. Isolation and culture of MSCs 
Three different cultures (named: 1, 2 and 3) of MSCs from human adipose tissue were 
analyzed according to the QCP proposed, as shown in Figure 1, for the manufacturing 
of a cellular medicine under GMP conditions. Three samples of adipose tissue were 
processed to carry out the ex vivo expansion. For each biological tissue sample a 
serological report was required. The results of the three samples were negative for 
Immunoglobulin M (IgM) A hepatitis, surface B Antigen, IgG C hepatitis and HIV; and 
positive for Anti HBc and Anti HBs. All materials and reagents necessary for the 
elaboration of the hMSCs were controlled, their sterility was analyzed and all results 
were negative, no microbiological growth was shown in any media (TSB and TSPB). 
Also, the endotoxin assay was performed and the results demonstrated that all materials 
and reagents were endotoxin free.  
For ex vivo expansion, different critical points have been defined: MCB, WCB and final 
cellular medicine, in each point the analytic techniques required to ensure the 
microbiological quality of the culture were proposed. Throughout the process a 
qualitative and quantitative environmental analysis of microbiological quality of air and 
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surfaces were carried out, the results were within the standards required by the GMP 
guidelines as previously described (25).  
 
2. Sterility test and Gram stain. 
Before carrying out the sterility test of samples, the effectiveness of two isolation media 
(TSB and TPSB) was demonstrated by growth promotion test with reference strains 
(Clostridium sporogenes, Pseudomonas aeruginosa, Staphylococcus aureus, Aspegillus 
niger, Bacillus subtilis and Candida albicans). Turbidity was observed in all media. On 
the other hand, sterility test of each medium was also satisfactory.  
After verification of the culture media, they were inoculated with the test sample of the 
different phases and, after 14 days incubation, none showed turbidity, so there was no 
evidence of microbial growth and the sterility of the cells was accepted for the three 
cultures. All negative control samples with NaCl were negative after the required 
incubation period. 
From the results of Gram stains no cfu were observed, in none of the three final cellular 
medicines studied. 
 
3. Detection of mycoplasma  
The presence of mycoplasma in each sample was analyzed by DNA amplification and 
the presence of 267 bp amplicon, none of the samples of the different phases showed 
presence of this band (data not shown).  A successful PCR was performed without 
polymerase inhibition.  Internal Control DNA was demonstrated by a 191 bp band in the 
gel, which verified extraction, reverse transcription, amplification, detection carried out 
since the internal control was added to the sample before isolating the nucleic acid.  
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4. Endotoxin assay 
The threshold of endotoxin was calculated using the formula Endotoxin Limit (EL) 
=K/M (27). Where K is the threshold pyrogenic dose of endotoxin per kilogram of body 
mass in one hour period and M is the maximum recommended dose of the product per 
kilogram of body mass in one hour period. For intravenous administration, the 
suggested value of K by the EP is 5.0 EU /kg · h and M was 1 mL/kg · h for the final 
cellular medicine manufactured in our laboratory, thus: 
EU= [5.0 EU /kg · h] / [1 mL/kg · h]; EU= 5.0 EU/mL  
The threshold of endotoxin was defined for each sample as 5.0 EU/mL. 
LAL used for the endotoxin assay had a sensibility of 0.03 EU/mL, which is lower than 
EL calculated in-house: 5.0 EU/mL, thereby, preventing false negatives. 
For the preparation of sample, MVD was calculated according to the formula:  
MVD = EL / λ = (5 EU/mL / 0.03 EU/mL)  = 166.7 
The sample could be diluted 166.7 times; in our method the selected dilution was 1:10, 
far below the permitted MVD. In each phase for ex vivo expansion, diluted samples 
were tested and including negative control no sample showed gelation except the two 
positive controls. 
In addition, a study of storage stability was performed; the concentration selected for 
this study (0.08 EU/mL) was based on the preparation of a concentration similar to 
positive control. The positive control was calculated according to the formula:  
2 λ= 2 x 0.03 EU/mL  
The positive control was 0.06 EU/mL. All samples showed gelation except the negative 
control samples for the duration of the study (6 months) at 4 ºC and −20 ºC. The 
gelation demonstrated the presence of endotoxin from E. coli. And therefore, the storage 
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conditions of a sample in a QCP defined for endotoxin assay were at 4 °C or −20 °C for 
a maximum of 6 months. 
 
5. Microbiological monitoring in process 
Results were interpreted according to the annex I-GMP, (Grade A: < 1 cfu/4 h and < 1 
cfu/glove, for environmental and staff monitoring respectively) (31).  
The effectiveness of the aseptic procedures has to be continuously evaluated in order to 
guarantee the safety of the medicine and to identify foci of contamination risk. The 
results obtained for environmental and staff monitoring during the ex vivo expansion of 
the three cultures were within the recommended specifications for microbial 
contamination in TSA and SDC. 
 
6. Validation of the analytical method 
Analytical methods described in pharmacopoeia monographs are considered validated; 
however, the laboratory must also confirm the procedure in-house with the samples for 
study in each technique initially, ensuring that there is no interference. 
 
6.1. Validation of sterility test. 
No antimicrobial activity was observed in the three cultures studied of any of the 
microorganisms tested. The media inoculated with the supernatant and the 
microorganisms presented a similar growth as in the promotion test, proving that the 
antibiotic present in the product does not interfere with the results of the sterility test.  
Gram stains of these media inoculated evidenced the microorganisms added. 
In the study of cell culture sterility, the presence of antibiotic in the expansion medium 
as microbial growth inhibitory substance must be taken into account. The antibiotic 
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concentration in 1 mL of supernatant was 100 UI/mL of penicillin G and 0.01 mg/mL of 
streptomycin, and was inactivated with 103 UI/mL of penicillinase contained in the 
medium (TPB and TPSB).  
Absence of false positive results confirmed the specificity of the test. The LOD was 
shown because all the microorganisms were grown at a concentration of 30 cfu/125 mL. 
The robustness was demonstrated satisfactorily by three replicates testing. 
 
6.2. Validation of mycoplasma detection 
The studied specificity by the kit manufacturer did not detect any of the 
phylogenetically related microorganisms, Clostridium, Lactobacillus and Streptococcus. 
To evaluate LOD, M. orale was selected in terms of the most possible source of 
contamination. The required LOD of 10 cfu/mL was reached in all conditions (n=24 
results: eight test replicates for each of the three samples) using different combinations 
of different reagents and reagent lots at different working dates by different analysts 
(Figure 2). On different days and with different samples, the same results were 
obtained; M. orale was detected with equal certainty. The results presented demonstrate 
the robustness of mycoplasma PCR-based test.  
 
6.3. Validation of endotoxin assay  
 
6.3.1. Confirmation of labelled lysate sensitivity 
Three batches of Pyrogent Ultra Gel Clot with labelled sensitivity of 0.03 EU/mL were 
evaluated with standard solutions. The standard solutions potency had been previously 
established using the current FDA Reference Standard Endotoxin. The results of these 
studies are described in Table II. The results from this study confirmed the λ. The 
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sensitivities measured were not less than 0.5 λ (0.015 EU/mL) and not more than 2 λ 
(0.06 EU/mL). 
 
6.3.2. Test for interfering factors 
The results of the assay are showed in Table III. Solution A was negative for three 
samples, which indicated no detectable endotoxin. The sensitivity was determined with 
solution B in the three cultures, which was not less than 0.5 λ (0.015 EU/mL) and not 
greater than 2 λ (0.06 EU/mL). The test solution did not contain interfering factors 
under the experimental conditions used. The sensitivity of the LAL was confirmed with 
solution C, and the negative control (solution D), was confirmed. 
For endotoxin test absence of interfering factors validated the specificity. The LOD was 
confirmed for an amoebocyte lysate sensitivity of 0.03 EU/mL and the robustness was 
demonstrated by three times satisfactory testing. The three analytical procedures 
(sterility, mycoplasma and endotoxin) satisfied the required characteristics for a limit 
test: specificity, LOD and robustness as shown in Table IV. 
 
Discussion 
 
The quality of any pharmaceutical product, including biological medicines as a CTMP, 
is established by the European Medicine Agency guidelines in conjunction with GMP 
guidelines and general chapters of the EP. In addition, each laboratory should establish 
a quality system tailored to their own process and the characteristic of the cellular 
medicine they are producing. 
Medicines are generally subjected to end-product batch testing as a means of quality 
control; in the case of a biologic medicine using stem cell, for clinical use, this control 
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must be amplified due to limitations inherent in the cells, such as viability, genetic 
stability related to extended culture time and microbiological contamination (32, 33). 
Microbiological contamination is one of the major risks associated with the 
administration of a CTMP. Therefore, it will be necessary to establish minimum 
standards of microbiological quality during the manufacture of these medicines through 
a QCP as proposed in this paper, encompassing microbiological analysis of biological 
sample, materials, reagents, intermediate and final product, as well as the environmental 
microbiological quality of air, surfaces and  staff (34).    
In this study, our results showed no microbiological contamination in any of the phases 
of cultures studied according to the QCP. In each of the three cultures studied, quality of 
adipose tissue sample was analyzed based on their serology and the existence of cellular 
pathogens and exogenous contaminants after the process of ex vivo expansion. 
Furthermore, all starting materials and reagents involved in the expansion process were 
tested for sterility and endotoxin and their traceability was followed (33, 35). 
A CTMP must be viable for its administration, besides being sterile (36, 37). So that the 
manufacture of these medicines should be carried out under aseptic conditions, in a 
clean room and under GMP conditions, preventing contamination of the medicine and 
ensuring its quality, which requires identifying and controlling the critical aspects of ex 
vivo expansion (38).  
A sterility test may be defined as a critical, the traditional method described in EP (18, 
38) for the sterility test takes 14 days, although other rapid methods have been 
published and supported in the last annex II of the GMP (39), which entail 7 days (40), 
however the “shelf-lives” of cells do not exceed 48 h. Therefore, the final cell medicine 
must be released parametrically (41), being necessary to provide all additional quality 
controls described in QCP to ensure that the medicine is free of contaminating 
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microorganisms at the time of release (42). Through sterility tests prior to release, in the 
intermediate phases (MCB and WCB) and on the starting material and reagents, besides 
endotoxin and mycoplasma assays, Gram stain and management of the monitorization 
process in the final cellular medicine, the absence of viable and actively 
microorganisms can be ensured (9).  
Regarding the contamination risk of a biologic medicine, mycoplasma contamination is 
a major problem (43, 44). It can produce a myriad of different effects with a dramatic 
alteration of biological characteristics of the contaminated cells: alteration of 
proliferation characteristics, immune reactions, viruses’ proliferation, chromosomal 
aberrations, and more besides. These organisms are resistant to most antibiotics 
commonly employed in cell cultures (19), therefore, it is essential to analyze both the 
intermediate products and the final medicine in the development of a CTMP to control 
disturbances not only to the cells, but also to the inhibition of cell growth and hence the 
difficulty to obtain the final dose. Although the incidence of mycoplasma infection in 
the cultures is low (45), in most cases having a human origin, making staff the major 
source of contamination, particularly Mycoplasma orale. Accordingly, staff should 
receive regular training for the aseptic manipulation of therapeutics (25). Also, both 
animal serum products and environment are possible sources of contamination (46).  
Endotoxin assay is another requirement for parenteral medicines. The endotoxin effects 
are different depending on the cell types. It can induce contractile dysfunction, and 
increased production of immunoglobulin light chains. Equally, the absence of bacterial 
endotoxins in a product implies the absence of pyrogenic components. 
We performed three successful validation runs to demonstrate the sensitivity, LOD and 
robustness of the method through the analytical technique validation (47). The 
validation parameters of different assays involved in the proposed QCP (sterility, 
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mycoplasma and endotoxin) demonstrated that the reagents used in each analytical 
technique were free of inhibitory factors and verified the suitability of each assay (48), 
based on the presence or absence of a detected analyte (49) by turbidity appearance, 
gelation after incubation, and/or detection of mycoplasama as band from PCR 
amplification. 
In conclusion, this work proposes a control plan to analyze the safety of hMSCs as 
cellular medicine for clinical use, based on the evaluation of bacteriological agent 
contamination throughout the manufacture process.  
The efficiency of the proposed QCP in this paper, carried out during the ex vivo 
expansion of three different cultures of hMSCs for the elaboration of autologous cell 
medicine under GMP conditions, has been premised on the standardization and 
validation in situ of each analytical technique, to ensure that the products are 
manufactured in a reliable and safe manner. Minimum controls of microbiological 
quality of the cells to be administered parenterally to patients have been established, 
encompassing both control samples and starting, intermediate and final material or 
products. Based on the QCP proposed, it was observed that the contamination risk could 
be prevented. 
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Legends of Figures and Tables 
 
Figure 1. Scheme of manufacturing process of autologous stem cell mesenchymal as a 
cell therapy medicinal product.   
 
Figure 2. Detection of PCR products by gel electrophoresis of 1 mL sample with 10 cfu 
Mycoplasma orale. Lane 1: negative control; Lanes 3 – 10: replicates 1−8 (10 cfu/mL);  
Lane 11: positive control; Lane 13: size marker 50 bp. The presence of mycoplasma in 
the sample was indicated by an amplification product at approximately 267 bp. A 
successfully performed PCR without polymerase inhibition was indicated by a 191 bp 
band (Internal Control DNA). Three individual sample batches were tested with 8 
replicates for each one. On different days the same results were obtained, Mycoplasma 
orale was detected with equal certainty. The Detection Limit (10cfu/mL) was 
confirmed.  
 
Table I. Microbial strains need to the Growth Promotion Test and the Validation of 
Sterility Test 
Table II. Results of calculated lysate sensitivity (LAL) 
Table III. Results test interfering factors 
Table IV.  Characteristics evaluated for the test validation according to ICH Q2 
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Tables 
 
Table I. Microbial strains need to the Growth Promotion Test and the Validation of 
Sterility Test 
 
Culture medium Microorganisms Strain 
Thioglycollate Penase Broth 
Clostridium sporogenes ATCC 11437 
Pseudomonas aeruginosa ATCC 9027 
Staphylococcus aureus ATCC 6538 
Tryptic Soy Penase Broth 
Aspegillus niger ATCC 16404 
Bacillus subtilis ATCC 6633 
Candida albicans ATCC 10231 
 
ATCC: American Type Culture Collection. 
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Table II. Results of calculated lysate sensitivity (LAL) 
 
BATCH OF 
LAL 
Endotoxin standard dilution 
(EU/mL) Endpoint 
EU/mL 
Log10 
Endpoint 
Mean 
Antilog10 
Mean 
0.06 0.03 0.015 0.0075 
1 
+ + − − 0.03 −1.52 
−1.29 0.05 
+ − − − 0.06 −1.22 
+ − − − 0.06 −1.22 
+ − − − 0.06 −1.22 
2 
+ + − − 0.03 −1.52 
−1.37 0.04 
+ + − − 0.03 −1.52 
+ − − − 0.06 −1.22 
+ − − − 0.06 −1.22 
3 
+ − − − 0.06 −1.22 
−1.29 0.05 
+ + − − 0.03 −1.52 
+ − − − 0.06 −1.22 
+ − − − 0.06 −1.22 
 
 
